By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Biomedical today announced its first-quarter revenues rose 67 percent year over year to C$2.5 million ($2.6 million).

The C$2.5 million figure compares to C$1.5 million in revenues from a year ago. Clinical product revenues increased to C$1.8 million from C$1.2 million, while non-clinical product revenues climbed to C$266,285 from C$188,125 a year ago. Contract service revenues rose to C$448,104 from C$146,945 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.